ALPS Group Inc

ALPS

Market cap $74M

When evaluating small-cap equity exposure, it's easy to gravitate towards the iShares Russell 2000 ETF (IWM) given its $82 billion in assets and 0.19% expense ratio. Yet, a closer look at another fund, the ALPS O'Shares U.S. Small-Cap Quality Dividend ETF (OUSM), reveals a fundamentally sound structural design that warrants closer attention.

TMX VettaFi Head of Research Todd Rosenbluth discusses thematic ETFs and the implications of VettaFi's acquisition of RAFI Indices on Schwab Network. VettaFi's RAFI Indices Acquisition and Fundamental Shift On June 11, VettaFi announced the acquisition of RAFI Indices, a deal expected to close in the coming weeks.

Agreement Marks Company's Expansion into Precision Oncology Testing, with the Goal of Establishing Malaysia's First Clinically Validated PDO Platform Agreement Marks Company's Expansion into Precision Oncology Testing, with the Goal of Establishing Malaysia's First Clinically Validated PDO Platform

Markets rally on ceasefire hopes, but should investors chase the headlines? ETFs can offer a balanced approach in a headline-driven market.

MyGenome Joins a Limited Number of Southeast Asian Laboratories Delivering WGS Under Internationally Recognized Clinical Standards, Strengthening its Position in Southeast Asian Genomics MyGenome Joins a Limited Number of Southeast Asian Laboratories Delivering WGS Under Internationally Recognized Clinical Standards, Strengthening its Position in Southeast Asian Genomics

AI is driving markets higher, but a handful of stocks are doing most of the heavy lifting. These ETFs offer a more balanced way to play the trend.

The AI trade continues to power markets, but rising concentration risks and volatile sentiment are making diversification increasingly important. Staying diversified with ETFs may be the smartest long-term move.

KUALA LUMPUR, Malaysia, May 19, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (the “Company” or “Alps Group”), the parent company of Alps Life Sciences Inc. (“Alps Holdco”), a fully integrated biotechnology research and healthcare platform specializing in predictive, preventive, and precision medicine, today announced that on May 15, 2026, the Company received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that based on the closing bid price of the ordinary shares of the Company for the last 30 consecutive business days, the Company is currently not in compliance with the continued listing requirement of Nasdaq under Nasdaq Listing Rules 5450(a)(1), which requires the Company to maintain a minimum bid price of $1.00 per share.

AI optimism and resilient earnings growth keep long-term optimism alive for U.S. equities. Discover ETFs to buy and hold for long-term growth.

Alps Group Inc (Nasdaq: ALPS) appoints former Ernst & Young Partner to its Board of Directors, strengthening governance and capital markets oversight.